Hims & Hers Health Beheer
Beheer criteriumcontroles 2/4
De CEO Hims & Hers Health is Andrew Dudum, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 14.40M, bestaande uit 4.2% salaris en 95.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 8.61% van de aandelen van het bedrijf, ter waarde $ 410.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 2.9 jaar.
Belangrijke informatie
Andrew Dudum
Algemeen directeur
US$14.4m
Totale compensatie
| Percentage CEO-salaris | 4.2% |
| Dienstverband CEO | 7.8yrs |
| Eigendom CEO | 8.6% |
| Management gemiddelde ambtstermijn | 2.7yrs |
| Gemiddelde ambtstermijn bestuur | 2.9yrs |
Recente managementupdates
Recent updates
Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Compensatie versus markt: De totale vergoeding ($USD 14.40M ) Andrew } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.60M ).
Compensatie versus inkomsten: De vergoeding van Andrew is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Andrew Dudum (35 yo)
7.8yrs
Tenure
US$14,401,411
Compensatie
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Financial Officer | 2.8yrs | US$7.43m | 0.051% $ 2.4m | |
| Chief Operating Officer | 3.8yrs | US$6.77m | 0.29% $ 13.7m | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$5.21m | 0.077% $ 3.7m | |
| Chief Medical Officer | 1.9yrs | US$198.26k | 0.088% $ 4.2m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.084% $ 4.0m | |
| Senior VP | 5.4yrs | US$961.12k | 0.0023% $ 111.4k | |
| Chief Communications Officer | 1.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Human Resources | 2.7yrs | geen gegevens | geen gegevens | |
| Senior VP & Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Chief Pharmacy & Innovation Officer | 1.9yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Mental Health | 1.7yrs | geen gegevens | geen gegevens |
2.7yrs
Gemiddelde duur
44yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HIMS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 3.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Medical Officer | 2.8yrs | US$198.26k | 0.088% $ 4.2m | |
| Senior VP & Member of Medical Advisory Board | 2.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.2yrs | US$194.26k | 0.025% $ 1.2m | |
| Lead Independent Director | 4.2yrs | US$227.41k | 0.071% $ 3.4m | |
| Independent Director | 3.7yrs | US$205.51k | 0.033% $ 1.6m | |
| Member of Medical Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 2.9yrs | geen gegevens | geen gegevens |
2.9yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HIMS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.